| Cover | Apr. 01, 2021 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | On April 1, 2021, Eloxx Pharmaceuticals, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”), reporting that, on April 1, 2021, the Company had acquired all of the issued and outstanding equity interests of Zikani Therapeutics, Inc. (“Zikani”), a Delaware corporation, pursuant to an Agreement and Plan of Merger, dated April 1, 2021. |
| Document Period End Date | Apr. 1, 2021 |
| Entity File Number | 001-31326 |
| Entity Registrant Name | Eloxx Pharmaceuticals, Inc. |
| Entity Central Index Key | 0001035354 |
| Entity Tax Identification Number | 84-1368850 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 950 Winter Street |
| Entity Address, City or Town | Waltham |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02451 |
| City Area Code | 781 |
| Local Phone Number | 577-5300 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, $0.01 par value per share |
| Trading Symbol | ELOX |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
